Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Mark Adley, Guy Jones & Fiona Measham. (2023) Jump-starting the conversation about harm reduction: making sense of drug effects. Drugs: Education, Prevention and Policy 30:4, pages 347-360.
Read now
Read now
Articles from other publishers (14)
Luke Turnock, Nick Gibbs, Luke Cox & Timothy Piatkowski. (2023) Big business: The private sector market for image and performance enhancing drug harm reduction in the UK. International Journal of Drug Policy 122, pages 104254.
Crossref
Crossref
Chinaza Godswill Awuchi, Maduabuchi Patrick Aja, Nancy Bonareri Mitaki, Sonia Morya, Ikechukwu O. Amagwula, Chinelo Kate Echeta & Victory S. Igwe. (2023) New Psychoactive Substances: Major Groups, Laboratory Testing Challenges, Public Health Concerns, and Community-Based Solutions. Journal of Chemistry 2023, pages 1-36.
Crossref
Crossref
Søren Holm, Margit Anne Petersen, Oskar Enghoff & Morten Hesse. (2023) Psychedelic discourses: A qualitative study of discussions in a Danish online forum. International Journal of Drug Policy 112, pages 103945.
Crossref
Crossref
Abu Shafi, Alex J. Berry, Harry Sumnall, David M. Wood & Derek K. Tracy. (2020) New psychoactive substances: a review and updates. Therapeutic Advances in Psychopharmacology 10, pages 204512532096719.
Crossref
Crossref
Avery Sapoznikow, Zachary Walsh, Kenneth W. Tupper, Earth Erowid & Fire Erowid. (2019) The influence of context on ayahuasca experiences: An analysis of experience reports. Journal of Psychedelic Studies 3:3, pages 288-294.
Crossref
Crossref
Margit Anne Petersen, Oskar Enghoff & Jakob Demant. (2019) The uncertainties of enhancement. Performance Enhancement & Health 6:3-4, pages 111-120.
Crossref
Crossref
Fabrizio Schifano, Flavia Napoletano, Stefania Chiappini, Laura Orsolini, Amira Guirguis, John Martin Corkery, Stefania Bonaccorso, Angelo Ricciardi, Norbert Scherbaum & Alessandro Vento. (2019) New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues. Current Addiction Reports 6:2, pages 140-152.
Crossref
Crossref
Maria Katselou, Ioannis Papoutsis, Panagiota Nikolaou, Nektaria Misailidi, Chara Spiliopoulou & Sotiris Athanaselis. (2018) Diphenidine: a dissociative NPS makes an entrance on the drug scene. Forensic Toxicology 36:2, pages 233-242.
Crossref
Crossref
Joanna Taylor & Claudia Pagliari. (2017) Mining social media data: How are research sponsors and researchers addressing the ethical challenges?. Research Ethics 14:2, pages 1-39.
Crossref
Crossref
Marie Claire Van Hout, Annemieke Benschop, Michal Bujalski, Katarzyna Dąbrowska, Zsolt Demetrovics, Katalin Felvinczi, Evelyn Hearne, Susana Henriques, Zsuzsa Kaló, Gerrit Kamphausen, Dirk Korf, Joana Paula Silva, Łukasz Wieczorek & Bernd Werse. (2017) Health and Social Problems Associated with Recent Novel Psychoactive Substance (NPS) Use Amongst Marginalised, Nightlife and Online Users in Six European Countries. International Journal of Mental Health and Addiction 16:2, pages 480-495.
Crossref
Crossref
Torsten Passie & Simon D. Brandt. 2018. New Psychoactive Substances. New Psychoactive Substances
69
110
.
Jason Wallach & Simon D. Brandt. 2018. New Psychoactive Substances. New Psychoactive Substances
305
352
.
Jason Wallach & Simon D. Brandt. 2018. New Psychoactive Substances. New Psychoactive Substances
261
303
.
Marie Claire Van Hout & Evelyn Hearne. (2017) New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors. International Journal of Drug Policy 40, pages 102-110.
Crossref
Crossref